Lupin's Nagpur unit-1 receives favorable FDA inspection report

Global pharmaceutical giant Lupin Limited (Lupin) has received a significant validation from the United States Food and Drug Administration (U.S. FDA). Lupin announced, that it has obtained the Establishment Inspection Report (EIR) for its Nagpur Unit-1 manufacturing facility, which specializes in the production of oral solid dosage forms.
 

The EIR was issued following the facility's latest inspection conducted in July 2023, and the U.S. FDA has classified the inspection as "Voluntary Action Indicated" (VAI). This favorable classification reflects Lupin's unwavering commitment to maintaining the highest standards of quality and compliance.

 

Nilesh Gupta, Managing Director of Lupin, expressed his satisfaction with the achievement, emphasizing Lupin's dedication to delivering top-quality healthcare solutions to patients worldwide. This positive development is a testament to Lupin's continuous efforts to ensure the integrity of its manufacturing processes and adherence to regulatory standards.

Top stories
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read . 02 Aug 2024 . 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read . 02 Aug 2024 . 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read . 02 Aug 2024 . 12:36 PM

Related Blogs
blog-logo

Share Market

blog-logo

10 mins read . 09 Dec 2024

What is the Bombay Stock Exchange?

  • 0 people read
blog-logo

Share Market

blog-logo

13 mins read . 09 Dec 2024

Stocks Under 5 Rupees in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions